|
Sep 18
|
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
|
|
Sep 17
|
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
|
|
Sep 16
|
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
|
|
Sep 13
|
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
|
|
Apr 15
|
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
|
|
Apr 11
|
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
|
|
Apr 10
|
Aptevo Therapeutics Provides Pipeline Update
|